May 2017

New Indications

Afinitor (everolimus) is now indicated for the treatment of progressive, unresectable or metastatic, well differentiated, nonfunctional neuroendocrine tumours of gastrointestinal or lung origin in adults.

Boostrix (diphtheria/ tetanus/ acellular pertussis (dTpa)) vaccine is now indicated for booster vaccination against diphtheria, tetanus and pertussis in individuals aged four years and older.

Stelara (ustekinumab (rmc)) is now indicated for the treatment of adults with moderately to severely active Crohn’s disease who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a TNFα antagonist or have medical contraindications to such therapies.

Zydelig (idelalisib) in combination with ofatumumab is now indicated for the treatment of adults with chronic lymphocytic leukaemia/ small lymphocytic lymphoma upon relapse in patients for whom chemo-immunotherapy is not considered suitable.

This list is a summary of only some of the changes that have occurred over the last month. Before prescribing, always refer to the full product information.

Copyright © MIMS Australia Pty Ltd. All rights reserved.

MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au